WASHINGTON (AP) — Federal regulators are challenging patents on 20 brand name drugs, including the blockbuster weight-loss injection Ozempic, in the latest action by the Biden administration targeting industry practices that drive up pharmaceutical prices.
The Federal Trade Commission on Tuesday sent warning letters to 10 drugmakers, taking issue with patents on popular drugs for weight loss, diabetes, asthma and other reparatory conditions. The letters allege that certain patents filed by Novo Nordisk, GlaxoSmithKline, AstraZeneca and seven other companies are inaccurate or misleading.
Brand-name drugmakers use patents to protect their medicines and stave off cheaper, generic medicines. Most blockbuster drugs are protected by dozens of patents covering various ingredients, manufacturing processes and intellectual property. Generic drugmakers can only launch their own cheaper versions if the patents have expired or are successfully challenged in court.
Related articles:
Related suggestion:
China Wins 6th Straight Women's Title at Table Tennis Team WorldsYoung Woman Saving Traditional Dyeing Craft from DyingPic Story of Bus Driver as National People's Congress DeputyYoung Woman Saving Traditional Dyeing Craft from DyingChinese paddlers shine at WTT Champions IncheonChina's Chen and Quan Win Women's 10m Platform Synchronised at Swimming WorldsAcross China: Rural Women Weave in Prosperous Lives Through EmbroideryWith Grand Slam Breakthrough, Emerging Zheng Leads Charge in China's Collective Tennis ChapterWoman Raises Goats to Help Vitalize Rural HometownRural School Teacher Heartens 'Left
1.8134s , 4667.1640625 kb
Copyright © 2024 Powered by US challenges 'bogus' patents on Ozempic and other drugs in effort to spur competition ,Worldly Winds news portal